insights_auto
Bakit tumaas ang ADAPY 7.14%?
Tingnan ang Higit pang Detalyechevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
$0.030
arrow_upward
+7.14%(+0.0020) 1D
Okt 9, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa ADAPY...
Buksan
$0.03
Mataas
$0.03
Mababa
$0.03
Mkt. cap
7.42M
Avg. na dami
207.06K
Dami
77.40K
Mataas nang 52-wk
$0.24
Mababa nang 52-wk
$0.00
Beta
0.75
Mga natitirang share
265.05M
Bilang ng mga empleyado
272
Buksan
$0.03
Mataas
$0.03
Mababa
$0.03
Mkt. cap
7.42M
Avg. na dami
207.06K
Dami
77.40K
Mataas nang 52-wk
$0.24
Mababa nang 52-wk
$0.00
Beta
0.75
Mga natitirang share
265.05M
Bilang ng mga empleyado
272
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
The Motley Fool
·
1 buwan ang nakalipas
History Says You Should Know These 3 Things Before Buying the Vanguard S&P 500 ETF (VOO)
Reuters
·
1 buwan ang nakalipas
S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
Bloomberg.com
·
5 araw ang nakalipas
S&P 500 Closes In on Record High as Tech Rallies: Markets Wrap
Investor's Business Daily
·
1 buwan ang nakalipas
Dow Jones Futures: Techs Set To Run? Nvidia, CrowdStrike, Okta, Salesforce Jump On Earnings
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Tungkol sa Adaptimmune Therapeutics PLC - ADR